Form 4: Royalty Pharma Director Henry A. Fernandez Acquires Shares in Lieu of Retainer

Director Henry A. Fernandez acquired 1,503 Class A Ordinary Shares of Royalty Pharma plc on December 31, 2024, in lieu of a quarterly retainer payment.

Summary

• On December 31, 2024, Henry A. Fernandez, a director of Royalty Pharma plc, acquired 1,503 Class A Ordinary Shares.
• The shares were issued under the Issuer's 2020 Independent Director Equity Incentive Plan.
• The acquisition was in lieu of a quarterly retainer payment of $37,500, with the shares acquired at a price of $24.9416 each.
• Following the transaction, Fernandez directly owns 55,505 Class A Ordinary Shares.
• Fernandez also indirectly owns 58,200 Class A Ordinary Shares through the Fernandez 2007 Children's Trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares is generally a good sign, indicating confidence in the company's future. The use of equity instead of cash is also a positive financial management strategy.

Positives

• The acquisition of shares by a director demonstrates confidence in the company.
• The use of equity in lieu of cash preserves the company's cash reserves.

Industry Context

Director share acquisitions are common in the pharmaceutical industry as a way to align management interests with shareholder value. Using equity in lieu of cash compensation is also a common practice to manage cash flow.

Stakeholder Impact

• Shareholders may view the director's share acquisition positively.
• The company benefits from preserving cash by issuing shares instead of paying cash retainers.

Key Dates